A Phase 1, Open-Label, Multiple-Dose, Dose-Escalation Study of MDX-1342 in Patients With CD19-Positive Refractory/Relapsed Chronic Lymphocytic Leukemia.
Phase of Trial: Phase I
Latest Information Update: 21 May 2013
At a glance
- Drugs MDX 1342 (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 08 Jan 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 26 Jun 2009 Planned end date changed from Sep 2009 to Mar 2011 as reported by ClinicalTrials.gov.
- 10 Jul 2008 Results are expected in 2009.